A non-secretory malignant insulinoma: a case report

Mohammad Zarei1, Majid Dastras2,*, Mostafa Roshanravan3

ABSTRACT
Introduction: We report a rare case of non-insulin secreting malignant insulinoma of the pancreas and discuss its medical and surgical management. Case Presentation: Our patient was a 62-year-old Persian female. Over the previous year, she had developed increased abdominal mass, dizziness, weakness, and fatigue. After surgical operation, chemotherapy was given to the patient. Treatment with cisplatin and etoposide was commenced in a 4-month course. Conclusion: As a result, chemotherapy showed an important role in the management of insulinoma. Key words: Insulinoma, Malignant, Pancreas

INTRODUCTION
Pancreatic endocrine tumors (PETs), with mild to moderate malignancies, originate from pancreatic islets. The first case was detected in 1869 by Langerhans. These tumors are rare and the prevalence is 1-4 per million people. Among all, insulinoma is the most common type and can be seen mostly in people between the ages of 30- to 60-year-old. Insulinoma accounts for only 1 percent of malignant pancreatic tumors and can occur with or without secretory function; and if it is combined with a hormonal syndrome, we considered it a secretory form. In non-secretory insulinoma, patients are asymptomatic until they develop gastric outlet obstruction or bile duct, or unless the tumor causes pain or are specified in imaging.

CASE PRESENTATION
A 62-year-old Persian female, who showed symptoms of headache, dizziness, fatigue and muscle jump about two years ago, had admitted in a hospital with a diagnosis of meningiomas and was operated to remove the mass. Over the previous year, she had developed increased abdominal mass, dizziness, weakness, and fatigue. This time, since the early studies on suspicion of insulinoma secretary, a fasting test was performed according to protocol. At first, the blood samples were collected to check for glucose, insulin and C-peptide levels of patient, and then fasting was given to patient under close supervision. It was recommended to measure the patient’s blood sugar in a serial form according to protocol if the symptoms of hypoglycemia persisted. Due to the normality of the test results, an abdominal Computed Tomography (CT) scan was requested to complete the studies. The CT scan showed a pancreatic tumor sized 13 x 8 mm along with extensive metastases to the surrounding area (Figure 1). For a definitive diagnosis, a needle biopsy and a pathologic examination were performed, and the malignant insulinoma diagnosis was confirmed. The dimension of the tumor was 6 x 5.8 x 13 mm. After surgical operation, chemotherapy was given to the patient. Treatment with cisplatin (I.V 170 mg/week) and etoposide (I.V 85 mg/daily) was commenced in a 4-month course. The current state of patient is acceptable and stable. Currently, the patient is under constant monitoring and care.

DISCUSSION AND CONCLUSIONS
Endocrine tumors comprise a small percentage (1-2%) of all pancreatic neoplasms. They are mostly seen in adults, but few cases have been reported in children and infants. Over all it is a rare tumor (with a prevalence of 1 in 250 million) and the annual incidence is 1 to 5 per million. 80% of cases were benign tumors and 40% of their size is below 1 cm. In a previous study, mean duration of symptoms before diagnosis was less than 1.5 years. However, some patients may be asymptomatic for decades. Approximately 20% of patients are misdiagnosed with neurological or mental disorder before the diagnosis of insulinoma.

The results of non-invasive centralization techniques including ultrasonography, CT and magnetic resonance imaging (MRI) have been desponding, and sensitivities ranging from 0 to 33% have been reported. In the present case, detection with CT Scan and final approval with needle biopsy was performed.
PET treatments include two-part problem solving: problems related to secreted hormones, and problems related to tumor growth and metastasis. Chemotherapy is one of the treatment methods that shows good result in patients. In our case, according to the symptoms of abdominal pain and swelling, and no proof of secretory insulinoma, treatment with chemotherapy in the same regimen to small cell lung cancer based on CT Scan showed positive outcome. As a result, chemotherapy showed an important role in the management of insulinoma.

ABBREVIATIONS
CT: Computed tomography
PET: Pancreatic endocrine tumor
MRI: Magnetic resonance imaging

COMPETING INTERESTS
The authors report no conflicts of interest in this work.

AUTHORS’ CONTRIBUTIONS
MZ and MD followed this case and drafted the manuscript; MZ and MR helped for the follow up of this case; MZ, MD, and MR revised this paper. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS
The authors wish to acknowledge the following individuals for their contributions to this case report.

REFERENCES
1. Pandey D, Sharma B, Kumar S, Chauhan V, Gupta D, Sharma A. Insulinoma Presenting with Psychiatric Symptoms. Journal of Indian Academy of Clinical Medicine. 2004;5(1):72–4.
2. Yao MM, Reynolds RH, et al. Insulinoma: a case report and review of the clinical features and diagnosis. Gundersen Lutheran Medical Journal. 2005;5:73–6.
3. Lever-Rosas CD, Enqvist-Pogan A, Chavaz-Rodrigue JJ, Galvan-Gonzalez JL, et al. Insulinoma-a case report. SevSanid-MilitMex. 2001;55:170–3.
4. Mittendorf EA, Liu YC, McHenry CR. Giant insulinoma: case report and review of the literature. J Clin Endocrinol Metab. 2005;90(1):575–80. Available from: 10.1210/jc.2004-0825.
5. Halder PJ, Hafeezunnisa P, Rai RM, Samii AB. Insulinoma. J Postgrad Med. 1992;38(4):202–4. Available from: 10.3109/00256199209145977.
6. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106(3):307–10. Available from: 10.1016/S0002-9343(99)00379-5.
7. Juan R. Rosai and Ackerman’s surgical pathology. New York: Mosby; 2004.
8. Sotolongo E, Capella C, Kloppe G. Tumors of the Pancreas. In: and others, editor. Atlas of tumor pathology. Washington DC: Armed forces institute of pathology; 1997. p. 120–130.
9. Schwartz S. Principles of surgery. Saunders Co.; 1999.
10. Correnti S. Intraoperative ultrasonography for pancreatic insulinoma. 43rd ed. and others, editor. Medline, Italy department of surgery; 1996.
11. Service FJ, McMahon MW, O’Brien PC, Ballard DJ. Functioning insulinomas, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9. Available from: 10.1016/S0025-6196(12)62083-7.
12. Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51(7):417–29. 180358.

13. Harrington MG, McGeorge AP, Ballantyne JP, Beastall G. A prospective survey for insulinomas in a neurology department. Lancet. 1983;1(8333):1094–5. 6133118. Available from: 10.1016/S0140-6736(83)91923-2.

14. Heeren JV. Pancreatic resection for carcinoma of the pancreas: whipples versus total pancreatectomy - an institutional perspective. World J Surg. 1994;8(6). Available from: 10.1007/BF01656028.

15. Wong LS, Hobbs S, Wright AD, Dorricott NJ. A non-insulin-secreting malignant insulinoma of the pancreas. Eur J Surg Oncol. 2000;26(3):314–6. 10753540. Available from: 10.1053/ejso.1999.0889.